๐Exciting times for NRx Pharmaceuticals! They're making strides in the development of NRX-101, a breakthrough therapy for suicidal bipolar depression & chronic pain.๐ฉโ๐ฌ๐
They've recently announced plans to submit a New Drug Application for NRX-100, a ketamine-based treatment for suicidal depression.๐๐ก
They're also working on a proprietary formulation of IV Ketamine, HTX-100. This new formulation has a neutral pH, unlike the acidic pH of generic ketamine, making it a game-changer.๐งช๐ฌ
NRXP announced successful results of its clinical trial of NRX-101 vs. lurasidone in the treatment of suicidal bipolar depression. With positive data, NRXP is now eligible to receive an additional $4 million from partners Alvogen, Inc. and Lotus Pharmaceuticals, Inc.๐ฐ๐
They're also tackling chronic pain with D-cycloserine, the active ingredient in NRX-101. It reduces chronic pain to levels previously associated with oral opioid drugs but without the addiction and side effects.๐๐
NRXP has also established HOPE Therapeutics to develop and launch IV Ketamine. They're planning to spin it out as a separate company, with term sheets received from prospective anchor investors for $60 million of new investment.๐ผ๐
NRXP delivered a 50% reduction in corporate overhead and 25% reduction in overall net loss in 2023, compared to 2024 with $0.20 per share improvement in negative earnings. They've added over $8 million in working capital.๐๐ช
They're planning to distribute shares of HOPE Therapeutics and royalty rights on Ketamine sales to existing NRx shareholders.๐๐
Stay tuned for more updates on NRXP's journey! ๐๐